A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Bladder cancer; Breast cancer; Cervical cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 19 Jun 2017 Planned End Date changed from 2 Mar 2018 to 19 Jan 2018.
- 19 Jun 2017 Planned primary completion date changed from 2 Mar 2018 to 19 Jan 2018.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.